[
 {
  "id": "NCT00744263#1",
  "nct": "NCT00744263",
  "found": true,
  "source": "EMA CHMP, Prevenar 13 variation assessment report, procedure EMEA/H/C/001104/II/0111 (EMA/CHMP/626561/2014), 2015; the trial's main publication is Bonten et al., N Engl J Med 2015;372:1114-25",
  "url": "https://www.ema.europa.eu/en/documents/variation-report/prevenar-13-h-c-1104-ii-0111-epar-assessment-report-variation_en.pdf",
  "period": "SAEs: within 28 days (1 month) after the single vaccination, all subjects; deaths: the whole double-blind case-acquisition period (mean follow-up 3.97 years per subject)",
  "serious": {
   "vaccine": 327,
   "vaccine_n": 42237,
   "placebo": 314,
   "placebo_n": 42255,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 3006,
   "vaccine_n": 42237,
   "placebo": 3005,
   "placebo_n": 42255,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "352 SAEs were reported for 327 subjects (0.8%) in the 13vPnC group, and 337 SAEs were reported for 314 subjects (0.7%) in the placebo group ... 3006 (7.1%) in the 13vPnC group and 3005 (7.1%) in the placebo group",
  "note": "Safety population: all subjects who received study vaccine and had any safety data. The SAE counts cover only the 28 days after vaccination, the only SAE window for all subjects; the death counts cover the roughly 4-year case-acquisition period, so the two windows differ. Deaths within 28 days of vaccination: 10 in each group. In the 2,011-subject immunogenicity subset, SAEs within 6 months: 70 of 1,006 vs 60 of 1,005. The report's consolidated table (28-day SAEs in everyone plus month 1 to 6 SAEs in the subset) gives 381 vs 359 subjects with any SAE and 21 vs 23 with a fatal SAE. No crossover is reported. The first part of the quote is the 28-day SAE sentence, the second the sentence on deaths during the case-acquisition period. The NEJM full text could not be opened (the publisher's site refused automated access) and its abstract gives no counts, so every number is from the EMA report."
 },
 {
  "id": "NCT00090233#1",
  "nct": "NCT00090233",
  "found": true,
  "source": "FDA CBER, Clinical Review of Biologics License Application STN 125122, RotaTeq (R. Tiernan), 30 January 2006; second source Vesikari et al., N Engl J Med 2006;354:23-33",
  "url": "https://webarchive.library.unt.edu/web/20090508034135/http://www.fda.gov/cber/review/rotamer020306rp2.pdf",
  "period": "Study 006 (REST), all vaccinated subjects, 'at any time' in blinded follow-up: SAEs were solicited for 42 days after each of three doses, and REST also captured SAEs, intussusception and deaths up to 365 days after dose 1",
  "serious": {
   "vaccine": 881,
   "vaccine_n": 35027,
   "placebo": 973,
   "placebo_n": 34978,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 24,
   "vaccine_n": 35027,
   "placebo": 27,
   "placebo_n": 34978,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "Study 006: Rota N=35027, Pla N=34978 ... # subjects with 1 or more SAE at any time: 881, 973 ... # Deaths at any time: 24, 27",
  "note": "FDA's own analysis (review Table 50) of everyone vaccinated in Study 006, including 382 subjects at three sites the applicant excluded and leaving out 73 cross-treated subjects (6 with an SAE, no deaths). Restricted to within 42 days of a dose, the same table gives 730 vs 751 subjects with an SAE and 14 vs 13 deaths. The NEJM paper rests on an earlier database (69,274 randomized) and reports SAEs in 803 of 34,035 vaccine and 859 of 34,003 placebo recipients (2.4% vs 2.5%) and 44 deaths (24 vs 20); its full text could not be opened, so the denominators are from its PubMed abstract and the counts from search-engine excerpts of the article (the death counts also appear in an AAP Grand Rounds summary). The FDA review was preferred because it covers the complete study population and follow-up. Blinding: one web-search summary displayed a registry row for this trial (SAE term 'Death', 1 of 34,904 vs 4 of 34,862); the registry was not opened and the row was not used."
 },
 {
  "id": "NCT04368728#1",
  "nct": "NCT04368728",
  "found": true,
  "source": "FDA CBER, BLA Clinical Review Memorandum, Comirnaty STN 125742/0 (Wollersheim and Schwartz), 2021; FDA CBER, sBLA Clinical Review Memorandum STN 125742/45 (ages 12-15), 2022; Thomas et al., N Engl J Med 2021;385:1761-73 with supplement",
  "url": "https://www.fda.gov/media/152256/download",
  "period": "blinded placebo-controlled follow-up from dose 1 to each participant's unblinding or the data cutoff, whichever came first: cutoff 13 March 2021 for participants 16 and older (up to about 6 months after dose 2; 58.2% had at least 4 months after dose 2), cutoff 2 September 2021 for ages 12-15",
  "serious": {
   "vaccine": 280,
   "vaccine_n": 23157,
   "placebo": 272,
   "placebo_n": 23150,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 16,
   "vaccine_n": 23157,
   "placebo": 15,
   "placebo_n": 23150,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "SAEs were reported by 268 (1.2%) and 268 (1.2%) of participants in the BNT162b2 and placebo groups ... A total of 29 deaths (15 BNT162b2, 14 placebo) occurred during the blinded, placebo-controlled period.",
  "note": "The fields are sums of counts the sources state separately for the trial's Phase 2/3 groups; no count was derived from a percentage. Components, vaccine / placebo: (a) 16 and older without HIV: N 21,926 / 21,921, SAE 268 / 268, deaths 15 / 14 (FDA BLA review Table 25 and sections 6.1.12.3-4; the deaths are also in Thomas et al. Table S4); (b) HIV-positive, 16 and older: N 100 / 100, SAE 2 / 2, deaths 1 / 1 (same review, Table 41); (c) ages 12-15: N 1,131 / 1,129, SAE 10 / 2, deaths 0 / 0 (FDA sBLA review Table 15, https://www.fda.gov/media/160341/download). Phase 1 groups (156 vaccine recipients across the BNT162b1 and BNT162b2 dose levels, 39 placebo) are NOT in the sums: Walsh et al., N Engl J Med 2020;383:2439-50 reports no SAE up to about 1 month after dose 2, and nothing later was found. Counts stop at unblinding: placebo recipients were then offered BNT162b2, and the open-label follow-up (about 12 further months for the vaccine groups, which the registry's time frame includes) is left out; over open-label follow-up to 13 March 2021 a further 3 original BNT162b2 recipients and 2 placebo recipients who had crossed over died. SAE and death counts cover the same blinded window. Through 1 month after dose 2 only, SAEs in group (a) were 127 / 116."
 },
 {
  "id": "NCT04505722#1",
  "nct": "NCT04505722",
  "found": true,
  "source": "Sadoff et al., N Engl J Med 2022;386:847-60 (final analysis), Supplementary Appendix Table S9; the same counts are in FDA's EUA amendment review memorandum for the Janssen booster, October 2021",
  "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8849184/",
  "period": "double-blind phase to data cutoff 9 July 2021; median follow-up 123 days (range 0-284) in the full analysis population, 25.8% with at least 6 months; participants censored at unblinding or on receiving another Covid-19 vaccine",
  "serious": {
   "vaccine": 223,
   "vaccine_n": 21898,
   "placebo": 265,
   "placebo_n": 21890,
   "basis": "stated",
   "usable": false,
   "why_not": "the published counts leave out COVID-19-related serious adverse events, so they are not participants with any serious adverse event"
  },
  "deaths": {
   "vaccine": 28,
   "vaccine_n": 21898,
   "placebo": 55,
   "placebo_n": 21890,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "Ad26.COV2.S N=21,898; Placebo N=21,890. Participants with >=1 SAE not related to Covid-19: 223 (1.0), 265 (1.2) ... Deaths: 28, 55",
  "note": "The SAE counts EXCLUDE Covid-19-related SAEs: the paper, its supplement and FDA's memorandum (https://www.fda.gov/media/153439/download) report only participants with at least one SAE not related to Covid-19. Janssen's briefing document for the 15 October 2021 FDA advisory committee (https://www.fda.gov/media/152954/download) adds that 14 vs 100 participants had SAEs associated with Covid-19 in the double-blind phase; a participant can be in both counts, so the number with any SAE is not stated anywhere found and was not computed. Deaths are all deaths reported in the double-blind phase (5 vs 22 of them Covid-19-related). Full analysis set: randomized and dosed. Placebo recipients were offered open-label vaccine after unblinding, and that follow-up is left out. The primary analysis (Sadoff et al., N Engl J Med 2021, cutoff 22 January 2021) covers a shorter period and was not used."
 },
 {
  "id": "NCT04652102#1",
  "nct": "NCT04652102",
  "found": true,
  "source": "Kremsner et al., Lancet Infect Dis 2022;22:329-40 (HERALD), Table 3 and appendix",
  "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8610426/",
  "period": "interim: from first dose (given 11 December 2020 to 12 April 2021) to data cutoff 18 June 2021, blinded; the planned SAE follow-up to 1 year after dose 2 (Day 393) has not been published",
  "serious": {
   "vaccine": 82,
   "vaccine_n": 19783,
   "placebo": 66,
   "placebo_n": 19746,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 8,
   "vaccine_n": 19783,
   "placebo": 6,
   "placebo_n": 19746,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "Any serious adverse event, overall: 82/19 783 (0·4%); 100 | 66/19 746 (0·3%); 76. Any adverse event with fatal outcome, overall: 8/19 783 (<0·1%) | 6/19 746 (<0·1%)",
  "note": "Phase 2b/3 safety analysis set: everyone who received at least one dose, analysed by what they actually received (25 participants assigned to placebo who got CVnCoV count as CVnCoV). Deaths are participants with a fatal adverse event; the appendix's table of reasons for stopping treatment lists only 2 vs 4 as died. These are interim counts, well short of the registry's Day 1 to Day 393 window: the paper says 1-year safety outcomes would be reported later, and no later journal article or regulator's review was found (CureVac stopped developing the candidate in October 2021). The table's footnote says SAEs run 'from immediately after the second dose' to the cutoff, while the methods and text describe SAEs in the whole safety set from vaccination. By the cutoff 2,558 placebo (13.0%) and 161 CVnCoV recipients (0.8%) had left the study for an authorised vaccine; no crossover inside the trial. SAE and death counts cover the same window."
 },
 {
  "id": "NCT05127434#1",
  "nct": "NCT05127434",
  "found": true,
  "source": "Wisch R, Ezenekwe A; FDA BLA Clinical Review Memorandum, mRESVIA (STN 125796/0), 2024",
  "url": "https://www.fda.gov/media/179653/download",
  "period": "Part A, vaccination to data cutoff 24 June 2023 (data extraction 13 Feb 2024); median safety follow-up 10.2 months (311 days, range 1 to 585); blinded and placebo-controlled throughout, but short of the trial's 24 months",
  "serious": {
   "vaccine": 1414,
   "vaccine_n": 18231,
   "placebo": 1438,
   "placebo_n": 18181,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 106,
   "vaccine_n": 18231,
   "placebo": 125,
   "placebo_n": 18181,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "SAEs: Entire study period 7.8 (1414/18231) 7.9 (1438/18181) ... Deaths: Entire study period 0.6 (106/18231) 0.7 (125/18181)",
  "note": "Table 13 of the review, Safety Set (all randomized participants who received any study product, grouped as received). SAEs and deaths cover the same window (vaccination to the cutoff). Deaths are counted in the Safety Set, not in all randomized. This is an interim cut: follow-up runs to Month 24 and I found no public account with counts for the whole 24 months (the 2024 and 2025 ACIP slides, the EMA variation reports, the 8/2026 US label, which still cites 311 days, and the 2026 Part B revaccination paper give none). Earlier cuts for comparison: EMA EPAR (cutoff 30 Apr 2023, median 257 days) SAE 1114 vs 1092 and fatal events 84 vs 83; Wilson et al., NEJM 2023 (cutoff 30 Nov 2022) SAE 2.8% in each group. The review's disposition table lists death as the reason for withdrawal in 97 vs 116. No crossover in Part A."
 },
 {
  "id": "NCT04516746#1",
  "nct": "NCT04516746",
  "found": true,
  "source": "Shoemaker K, et al., Vaccines (Basel) 2024;12:883 (final 2-year analysis, Table 1 and Supplementary Table S3); same counts in AstraZeneca Clinical Study Report Synopsis D8110C00001, edition 2.0, 2023",
  "url": "https://www.mdpi.com/2076-393X/12/8/883",
  "period": "first dose to first non-study COVID-19 vaccination or study end, whichever came first (final analysis, database lock 21 March 2023); median follow-up after first dose 328 days AZD1222, 100 days placebo; censored at non-study vaccination, not at unblinding",
  "serious": {
   "vaccine": 621,
   "vaccine_n": 21587,
   "placebo": 136,
   "placebo_n": 10793,
   "basis": "stated",
   "usable": false,
   "why_not": "the published window is censored at non-study vaccination, not at unblinding, which leaves the arms very unequal time at risk (20,223 against 3,893 patient-years)"
  },
  "deaths": {
   "vaccine": 42,
   "vaccine_n": 21587,
   "placebo": 14,
   "placebo_n": 10793,
   "basis": "stated",
   "usable": false,
   "why_not": "the published window is censored at non-study vaccination, not at unblinding, which leaves the arms very unequal time at risk (20,223 against 3,893 patient-years)"
  },
  "quote": "Prior to non-study COVID-19 vaccination, N = 21,587: AEs with outcome of death 42 (0.2) ... SAEs 621 (2.9). Placebo, N = 10,793: 14 (0.1) ... 136 (1.3)",
  "note": "Safety population (at least one dose, as treated). No published table isolates the strictly double-blind period at the final analysis; 'prior to non-study COVID-19 vaccination' is the closest published window to the placebo-controlled period, but it runs past unblinding for anyone who took no other vaccine, and follow-up is very unequal (20,223 vs 3,893 patient-years). Deaths are 'AEs with outcome of death', over the same window as SAEs. The same tables' Overall columns (whole 2 years, including time after non-study vaccination, unblinded): SAE 1039 vs 467, deaths 62 vs 33. Earlier cuts: 6-month analysis (Sobieszczyk et al., J Clin Invest 2022, cutoff 30 Jul 2021, Supplemental Table 5, same censoring) SAE 353 vs 121, deaths 14 vs 8; primary analysis (cutoff 5 Mar 2021, CSR synopsis) deaths 7 vs 7 in the blinded period, safety set 21,587 vs 10,792. By study end 84.1% of placebo and 67.9% of AZD1222 recipients had taken a non-study vaccine; there was no in-study crossover. Blinding: a web-search summary showed me this trial's registry SAE and death counts before I had a source; the window was chosen on the definition above and the counts are read from the cited tables."
 },
 {
  "id": "NCT04614948#1",
  "nct": "NCT04614948",
  "found": true,
  "source": "FDA, Emergency Use Authorization Amendment Review Memorandum, Ad26.COV2.S booster dose (study COV3009), 2021; Hardt K, et al., Lancet Infect Dis 2022;22:1703-15 (appendix Table S10)",
  "url": "https://www.fda.gov/media/153439/download",
  "period": "double-blind phase, first dose to data cutoff 25 June 2021 (enrolment began 16 Nov 2020); median follow-up 70 days after dose 1; 98% of participants unblinded by the cutoff",
  "serious": {
   "vaccine": 104,
   "vaccine_n": 15705,
   "placebo": 136,
   "placebo_n": 15588,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 4,
   "vaccine_n": 15705,
   "placebo": 13,
   "placebo_n": 15588,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "among 15705 vaccine recipients and 15588 placebo recipients ... a total of 104 participants reported one or more SAEs in the vaccinated group ... and 136 participants reported one or more SAEs in the placebo group",
  "note": "Deaths, same memo: 'During the blinded phase of the study, there were four deaths in the vaccinated group ... and 13 deaths in the placebo group'. Full analysis set as analysed for safety: 31,300 vaccinated (15,708 and 15,592) less 7 who had a COVID-19 vaccine outside the study before the first study dose (3 Ad26.COV2.S, 4 placebo), who were excluded from the safety outputs; these 7 are the registry's two 'Non-FAS' groups, so pooling them back gives 15,708 and 15,592. The SAE counts come from the FDA memo, which took them from the sponsor's study report and did not verify them from the datasets; the Lancet paper gives only related SAEs (8 vs 3) and deaths (4 vs 13), with the same denominators (appendix Table S10, DOI 10.1016/S1473-3099(22)00506-0). SAEs and deaths cover the same window. After unblinding, placebo recipients were offered open-label Ad26.COV2.S; four more deaths after Ad26.COV2.S fell in the open-label phase and are not counted here."
 },
 {
  "id": "NCT04470427#1",
  "nct": "NCT04470427",
  "found": true,
  "source": "Zhang R, Goswami J; FDA BLA Clinical Review Memorandum, Spikevax (STN 125752), 2022; El Sahly HM, et al., N Engl J Med 2021;385:1774-85",
  "url": "https://www.fda.gov/media/156342/download",
  "period": "Part A (blinded phase): dose 1 to unblinding or participant decision visit, discontinuation, or data cutoff 26 March 2021; median blinded follow-up 148 days after dose 1",
  "serious": {
   "vaccine": 268,
   "vaccine_n": 15184,
   "placebo": 292,
   "placebo_n": 15162,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 16,
   "vaccine_n": 15184,
   "placebo": 16,
   "placebo_n": 15162,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "SAEs during Part A 268/15184 (1.8) 292/15162 (1.9) ... Deaths during Part A 16/15184 (0.1) 16/15162 (0.1)",
  "note": "Table 29 of the review, Safety Set (randomized, at least one dose, grouped as received). El Sahly et al. give the same safety population (15,184 and 15,162) and '16 deaths each (0.1%)' by completion of the blinded phase; the paper's main text has no overall SAE count. Safety data were cut at 26 March 2021 but deaths were monitored to the database lock of 4 May 2021; the 16 vs 16 are deaths during Part A. One further mRNA-1273 death had its event onset in Part A and occurred in Part B, and is not among the 16. The review's efficacy section separately gives 12 vs 12 deaths in its all-cause mortality analysis, a different analysis set. Placebo recipients were offered mRNA-1273 at the participant decision visit (Part B); events in placebo recipients after unblinding but before their first mRNA-1273 dose were still counted in Part A (77 events)."
 },
 {
  "id": "NCT04908683#1",
  "nct": "NCT04908683",
  "found": true,
  "source": "Comeaux CA, et al., EBioMedicine 2026;133:106513",
  "url": "https://doi.org/10.1016/j.ebiom.2026.106513",
  "period": "vaccination to the final database cut-off, 20 July 2023 (study stopped early in March 2023; blinded and placebo-controlled throughout); every participant had at least 6 months of safety follow-up and fewer than 1% reached the planned 24 months",
  "serious": {
   "vaccine": 842,
   "vaccine_n": 16709,
   "placebo": 457,
   "placebo_n": 8367,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 105,
   "vaccine_n": 16709,
   "placebo": 61,
   "placebo_n": 8367,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "SAEs, AESIs, and AEs leading to discontinuation (FAS, until database cut-off) n = 16,709 n = 8367 ... SAE 842 (5.0) 457 (5.5) ... AE with fatal outcome 105 (0.6) 61 (0.7)",
  "note": "Table 2, full analysis set at the final analysis. Deaths are 'AE with fatal outcome', not a separate all-cause mortality count. The Methods say SAEs were collected from Day 1 until 6 months after vaccination, while AEs leading to study discontinuation were recorded to the end of the study, so the SAE window may be shorter than the deaths window although the table heads both 'until database cut-off'. The abstract's 23,555 vaccinated (15,698 and 7,857) is the primary analysis (cutoff 15 Sept 2022); the final set is larger. No crossover. Blinding: a web-search summary showed me this trial's registry SAE counts before I found the paper; the counts here are read from the paper's table."
 },
 {
  "id": "NCT04886596#1",
  "nct": "NCT04886596",
  "found": true,
  "source": "Ison MG, Papi A, et al. (AReSVi-006 study group), Lancet Respiratory Medicine, 2025 (deaths and denominators); FDA/CBER review presentation to VRBPAC, 2023 (SAE counts)",
  "url": "https://doi.org/10.1016/S2213-2600(25)00048-7",
  "period": "Deaths: dose 1 to trial end (31 May 2024), three RSV seasons, median about 31 months. SAEs: only the 6 months after dose 1, at the data lock of 30 April 2022",
  "serious": {
   "vaccine": 522,
   "vaccine_n": 12467,
   "placebo": 506,
   "placebo_n": 12499,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 231,
   "vaccine_n": 12469,
   "placebo": 265,
   "placebo_n": 12503,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "Fatal serious adverse event 111 1·8 (1·5–2·1) 120 1·9 (1·6–2·3) 265 2·1 (1·9–2·4) [Table 3: single-dose N=6226, revaccination N=6243, placebo N=12 503]",
  "note": "Exposed population (received dose 1): 12,469 vaccine (single-dose 6,226 plus revaccination 6,243, pooled) and 12,503 placebo. Deaths are participants with a fatal SAE from dose 1 to trial end: 111 + 120 = 231 vaccine, 265 placebo. SAE counts cover a much shorter window than deaths. The trial collected all SAEs only for 6 months after each dose, and no source read gives participants with an SAE after any dose. The SAE counts given are for the 6 months after dose 1 only, from the FDA review slide 'Study 006: Safety Overview' (https://www.fda.gov/media/165731/download: up to 6 months 522 (4.2) vs 506 (4.0)), whose denominators are 12,467 and 12,499 (exposed set at that lock); they match the 4.2% and 4.0% of Papi et al., NEJM 2023. After dose 2 (Ison et al., Clin Infect Dis 2024, PMC11175669), SAEs within 6 months were 210/4,966 (revaccination), 219/4,991 (single-dose) and 461/10,033 (placebo). No crossover: placebo recipients stayed on placebo. The Lancet paper was read from the repository copy at https://research.dial.uclouvain.be/bitstreams/f0c47218-94c3-43b8-b034-5f4d8cbe7189/download; its appendix was not available."
 },
 {
  "id": "NCT04904549#1",
  "nct": "NCT04904549",
  "found": true,
  "source": "Dayan GH, Rouphael N, Walsh SR, et al., eClinicalMedicine, 2023 (Stage 1, monovalent) and Dayan GH, Rouphael N, Walsh SR, et al., Lancet Respiratory Medicine, 2023 (Stage 2, bivalent)",
  "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10626161/",
  "period": "Blinded follow-up to each stage's analysis cut-off: Stage 1 to 28 January 2022 (median 165 days after dose 1); Stage 2 to 15 March 2022 (median 85 days after dose 1)",
  "serious": {
   "vaccine": 72,
   "vaccine_n": 11522,
   "placebo": 102,
   "placebo_n": 11514,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 4,
   "vaccine_n": 11522,
   "placebo": 15,
   "placebo_n": 11514,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "SAE 42/5050 0.8 (0.6; 1.1) 76/5064 1.5 (1.2; 1.9) … Death 0/5050 0 (0; 0.1) 9/5064 0.2 (0.1; 0.3) [Stage 1, Table 3]",
  "note": "Each number is the sum of the two stages' safety analysis sets (SafAS, by vaccine received). Stage 1: vaccine 5,050, placebo 5,064; SAE 42 vs 76; deaths 0 vs 9. Stage 2 (author manuscript at https://pmc.ncbi.nlm.nih.gov/articles/PMC10872639/, Table 2): vaccine 6,472, placebo 6,450; SAE 30 vs 26; deaths 4 vs 6. Both are interim cut-offs, far shorter than the registry's 387-day frame, and no publication of the full follow-up was found. Neither paper describes crossover, but the trial's title and the registry's time frame name a later open-label crossover and booster part, so later follow-up is not placebo-controlled. Blinding lapse: a web-search summary displayed the registry's Stage 1 SAE counts before extraction; they were not used."
 },
 {
  "id": "NCT00534248#1",
  "nct": "NCT00534248",
  "found": true,
  "source": "Schmader KE, Levin MJ, Gnann JW Jr, et al., Clinical Infectious Diseases, 2012",
  "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4542655/",
  "period": "SAEs: days 1 to 182 after vaccination. Deaths: whole study (mean follow-up 1.3 years, range 0 days to 2 years)",
  "serious": {
   "vaccine": 233,
   "vaccine_n": 11094,
   "placebo": 211,
   "placebo_n": 11116,
   "basis": "computed",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 18,
   "vaccine_n": 11094,
   "placebo": 30,
   "placebo_n": 11116,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "fatal SAEs over the duration of the study (18 in ZV group, 30 in placebo group)",
  "note": "Denominators are subjects vaccinated with safety follow-up (Table 3). The SAE counts are COMPUTED, not stated: the paper gives the 182-day SAE proportions only as 2.1% (vaccine) and 1.9% (placebo), relative risk 1.11. 2.1% of 11,094 = 233 and 1.9% of 11,116 = 211; rounding allows 228 to 238 and 206 to 216, and this assumes the 182-day proportions use the Table 3 denominators. Stated exactly for days 1 to 42 (Table 3): SAEs 69 (0.6%) vs 61 (0.5%), deaths 1 vs 3. SAEs cover a shorter window than deaths, which are fatal SAEs over the whole study. The US package insert (https://www.fda.gov/media/82524/download) gives 11,184 and 11,212 vaccinated and the same 42-day percentages; no count for the 182-day window was found there or in Merck's release. No crossover is described."
 },
 {
  "id": "NCT01374516#1",
  "nct": "NCT01374516",
  "found": true,
  "source": "Sanofi Pasteur, clinical study report synopsis for CYD15 (results summary, issued 11 June 2020)",
  "url": "https://www.sanofi.com/assets/dotcom/content-app/clinical-studies/pasteur/Letter-T/CYD15-results-summary.pdf",
  "period": "Entire study, first injection to end of follow-up (about 72 months; 8 June 2011 to 5 March 2018): 25-month active phase, then hospital phase and surveillance expansion period",
  "serious": {
   "vaccine": 1765,
   "vaccine_n": 13915,
   "placebo": 911,
   "placebo_n": 6939,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "deaths": {
   "vaccine": 42,
   "vaccine_n": 13915,
   "placebo": 27,
   "placebo_n": 6939,
   "basis": "stated",
   "usable": true,
   "why_not": null
  },
  "quote": "During the entire study … SAE 1765/13915 12.7 (12.1; 13.2) 911/6939 13.1 (12.3; 13.9) … Death 42/13915 0.3 (0.2; 0.4) 27/6939 0.4 (0.3; 0.6)",
  "note": "Safety Analysis Set (at least one injection, by product received), table 'Safety overview after any injection - SafAS'. SAEs and deaths cover the same period. By phase: active phase (to 25 months, the period of Villar et al., NEJM 2015) SAE 571/13,915 vs 311/6,939 and deaths 6 vs 6; hospital phase and surveillance expansion period SAE 1,297/13,296 vs 650/6,644 and deaths 36 vs 21. The synopsis describes no crossover; placebo recipients stayed in the control group throughout."
 },
 {
  "id": "NCT02747927#1",
  "nct": "NCT02747927",
  "found": true,
  "source": "Biswal S, Borja-Tabora C, Martinez Vargas L, et al., Lancet, 2020 (abstract only; full text and appendix paywalled); per-arm denominators from Tricou V, et al., Lancet Global Health, 2024",
  "url": "https://doi.org/10.1016/S0140-6736(20)30414-1",
  "period": "Parts 1 and 2: first dose to 18 months after the second dose (about 21 months), double-blind",
  "serious": {
   "vaccine": 535,
   "vaccine_n": 13380,
   "placebo": 321,
   "placebo_n": 6687,
   "basis": "computed",
   "usable": false,
   "why_not": "computed from an abstract's percentages with denominators from another report, and a regulator's report gives another percentage for the vaccine arm"
  },
  "deaths": {
   "vaccine": null,
   "vaccine_n": null,
   "placebo": null,
   "placebo_n": null,
   "basis": null,
   "usable": false,
   "why_not": "not found"
  },
  "quote": "serious adverse events were similar in TAK-003 (4·0%) and placebo (4·8%) recipients",
  "note": "The SAE counts are COMPUTED, not stated: only the abstract of the Lancet paper could be read, and it gives percentages alone (safety set 20,071 in all). 4.0% of 13,380 = 535 and 4.8% of 6,687 = 321; rounding allows 529 to 541 and 318 to 324. The per-arm safety-set sizes come from the same trial's later report (Tricou 2024) and the EMA assessment report for Qdenga (EMA/862552/2022), whose text gives 4.8% for both arms up to 18 months, probably a typo for the vaccine arm. Deaths in Parts 1 and 2 are not stated in any source read. EMA reports 13 deaths (10 vaccine, 3 placebo) up to 36 months after dose 2, and Rivera et al., Clin Infect Dis 2022, 7 (5 vaccine, 2 placebo) in months 19 to 36 after dose 2; that would leave 5 and 1, but it is a subtraction across sources, not a reported count. Parts 1 and 2 were chosen because the registry group is 'TDV (Part 1)', with SAEs and deaths to the end of Part 2; blinded placebo-controlled follow-up went on through Part 3, with no crossover. Part 3 alone, stated exactly (about months 22 to 57 after dose 1; Tricou 2024): SAEs 664/13,380 vs 396/6,687, deaths 11 vs 6, with SAE collection there limited to deaths, related SAEs and SAEs judged relevant. No count for Parts 1 to 3 together was found."
 }
]